Nonclinical development of a biosimilar: the current landscape.
about
Is the decision on the use of biosimilar growth hormone based on high quality scientific evidence? - a systematic review.Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab).Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.Biosimilars for psoriasis: preclinical analytical assessment to determine similarity.
P2860
Nonclinical development of a biosimilar: the current landscape.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Nonclinical development of a biosimilar: the current landscape.
@en
Nonclinical development of a biosimilar: the current landscape.
@nl
type
label
Nonclinical development of a biosimilar: the current landscape.
@en
Nonclinical development of a biosimilar: the current landscape.
@nl
prefLabel
Nonclinical development of a biosimilar: the current landscape.
@en
Nonclinical development of a biosimilar: the current landscape.
@nl
P2860
P356
P1433
P1476
Nonclinical development of a biosimilar: the current landscape.
@en
P2093
Anita O'Connor
Mark Rogge
P2860
P304
P356
10.4155/BIO.13.7
P577
2013-03-01T00:00:00Z